Dextrothyroxine

Dextrothyroxine
Clinical data
Trade names	Choloxin
Other names	D-3,5,3',5'-tetraiodothyronine
AHFS/Drugs.com	Multum Consumer Information
ATC code	C10AX01 (WHO) ;
Legal status
Legal status	Discontinued;
Identifiers
	IUPAC name (2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid;
CAS Number	51-49-0;
PubChem CID	8730;
DrugBank	DB00509;
ChemSpider	8402;
UNII	4W9K63FION;
ChEBI	CHEBI:30659;
ChEMBL	ChEMBL559;
CompTox Dashboard (EPA)	DTXSID60199000 ;
ECHA InfoCard	100.000.094
Chemical and physical data
Formula	C15H11I4NO4
Molar mass	776.87 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)[C@H](N)Cc2cc(I)c(Oc1cc(I)c(O)c(I)c1)c(I)c2;
	InChI InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m1/s1; Key:XUIIKFGFIJCVMT-GFCCVEGCSA-N;

Dextrothyroxine (trade name Choloxin) saw research as a cholesterol-lowering drug^[1]^[2] but was pulled due to cardiac side-effects. It also increases hepatic lipase which in turn improves utilization of triglycerides, improving apolipoprotein E cholesterol particles.^{[citation needed]}

References

^ Bantle, J. P.; Hunninghake, D. B.; Frantz, I. D.; Kuba, K.; Mariash, C. N.; Oppenheimer, J. H. (1984). "Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia". The American Journal of Medicine. 77 (3): 475–481. doi:10.1016/0002-9343(84)90107-4. PMID 6475988.
^ Bommer, C.; Werle, E.; Walter-Sack, I.; Keller, C.; Gehlen, F.; Wanner, C.; Nauck, M.; März, W.; Wieland, H.; Bommer, J. (1998). "D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients". Journal of the American Society of Nephrology : JASN. 9 (1): 90–96. PMID 9440092.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.